Sarah Birchall

Suggest Changes
Learn More
OBJECTIVES SMT19969 is a novel antimicrobial under clinical development for the treatment of Clostridium difficile infection (CDI). The objective was to determine the comparative susceptibility of 82(More)
  • 1